TapImmune Inc. Share Price OTC Bulletin Board
Stocks
TPIV
US8760334081
Biotechnology & Medical Research
| Market Cap | 20.67M 18.12M 16.82M 15.45M 29.12M 2B 29.55M 200M 78.41M 976M 77.61M 75.94M 3.37B | P/E 2026 * |
-1.29x | P/E 2027 * | -1.22x |
|---|---|---|---|---|---|
| Enterprise Value | 20.67M 18.12M 16.82M 15.45M 29.12M 2B 29.55M 200M 78.41M 976M 77.61M 75.94M 3.37B | EV / Sales 2026 * |
7.3x | EV / Sales 2027 * | 1.03x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: TapImmune Inc.
| 20/08/21 | Wall Street hoger gesloten | |
| 20/08/21 | Wall Street koerst af op hoger slot | |
| 20/08/21 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 30/04/2023 |
| Chief Operating Officer | 36 | 30/11/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 16/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 23/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 05/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 21.17M | |
| -4.89% | -7.74% | -3.35% | +9.27% | 48.5B | |
| -0.14% | -0.76% | +378.26% | +583.71% | 38.97B | |
| +0.39% | +2.79% | +8.23% | +61.99% | 35.43B | |
| -1.54% | -4.01% | +5.95% | -13.03% | 33.65B | |
| -0.87% | -3.19% | -1.27% | +29.16% | 26.58B | |
| -1.28% | -6.20% | - | - | 16.82B | |
| -0.67% | -0.21% | +10.55% | +115.31% | 15.18B | |
| +1.32% | +1.85% | +11.40% | +15.52% | 13.89B | |
| +0.40% | -2.79% | +3.58% | -31.98% | 12.76B | |
| Average | -0.73% | -1.76% | +51.67% | +96.24% | 26.87B | |
| Weighted average by Cap. | -1.29% | -1.77% | +68.45% | +121.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.83M 2.48M 2.3M 2.12M 3.99M 273M 4.05M 27.43M 10.73M 134M 10.62M 10.4M 462M | 20.09M 17.6M 16.34M 15.01M 28.29M 1.94B 28.71M 195M 76.18M 948M 75.4M 73.77M 3.28B |
| Net income | -19.36M -16.96M -15.75M -14.47M -27.27M -1.87B -27.67M -188M -73.43M -914M -72.68M -71.12M -3.16B | -19.89M -17.43M -16.18M -14.87M -28.02M -1.92B -28.43M -193M -75.44M -939M -74.67M -73.06M -3.24B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
